Entries by Caroline Hewitt

Biosimilar Adoption Within the Oncology Industry

Growth within the biosimilar market increases with the adoption of these prescription alternatives by oncologists and other healthcare leaders who are taking the initiative to improve cost-savings for millions of cancer patients. AON is one such organization that is taking the lead to publicize the benefits — including the cost savings — of biosimilars.

In Community-Based Study, Switching to Ixazomib in Newly Diagnosed MM Brought Improved Responses Across Age Groups

A recent article by The American Journal of Managed Care (AJMC), summarizes an analysis presented during the 64th American Society of Hematology Annual Meeting and Exposition and co-authored by Ruemu E. Birhiray, MD of Hematology Oncology of Indiana showing that patients with multiple myeloma were able to experience improved responses to the proteasome inhibitor ixazomib after switching from bortezomib.

What Does the URAC Re-Accreditation Mean for You?

AON’s in-house specialty pharmacy announced it has received re-accreditation through URAC, Utilization Review Accreditation Commission. Striving for the highest standards of patient care and safety is the top priority for AON, and accreditations are a means of building trust with patients who come to AON practices for their cancer care and treatments.

Diagnosed With Breast Cancer? Ask These Eight Questions

One in eight women will receive a breast cancer diagnosis in her lifetime, according to the National Breast Cancer Foundation. Early detection and prevention plans are important for slowing the progression of the disease and increasing the rate of survival. Additionally, asking the right questions when diagnosed with cancer is critical, providing essential information for patients who are beginning their journey to recovery.